. Interactions between platelets with injured vascular endothelium contribute to thrombotic occlusion. A murine monoclonal antibody [7E3 F(ab'),] to the platrlet GPIIb/IIIa receptor complex was used to inhibit platelet aggregation in an experimental model of coronary artery thrombosis. Prevention of thrombotic occlusion by 7E3 F(ab'), (0.8 mg/kg bolus i.v.) was studied in dogs with direct current induced intimal injury (100 PA for 5 h) and critical stenosis of the left circumflex coronary artery (LCCA).
Baseline LCCA blood flow (CBF) was similar in 7E3 F(ab'), and control groups, but decreased in the controls [24 + 2 ml/min to 0 + 0 ml/min, n = 13 (mean ~s.E.M.)] due to thrombotic occlusion in each case (time to thrombosis 136 f 15 min). In the group treated with 7E3 F(ab'),, CBF did not change significantly (27 + 3 ml/min to 22 k 3 ml/min, a = 6) and thrombotic occlusion did not occur during the 5-h observation period in which intimal injury was produced in the LCCA (P < 0.001). Oscillations in CBF preceded thrombosis in the control group, but did not occur with 7E3 F(ab'), treatment (2.2 + 0.7 vs. 0 + 0, P < 0.05). The thrombus mass recovered from the LCCA 30 min after occlusion was 8.8 + 1.3 mg in the controls compared to 2.2 & 1.2 mg determined 5 h after administration of 7E3 F(ab')s (P < 0.05). When studied ex uivo, before the administration of the test agents, platelets from both groups of dogs aggregated in response to ADP and arachidonic acid. However, after treatment, the ex viva aggregation of platelets from 7E3 F(ab'), animals was inhibited whereas platelets from the control animals continued to aggregate ex tiuo throughout the period of the experimental protocol (P < 0.05). The labeling of platelets with "'iridium showed accumulation of radioactivity within the thrombus and upon the vascular endothelium which was less in 7E3 F(ab'), treated dogs as compared to the control group (P < 0.05). The murine monoclonal antibody 7E3 F(ab')s did not affect hemodynamic values or the circulating platelet count during the experimental protocol.
In conclusion, antibody to platelet GPIIb/IIIa receptors:
(1) prevented thrombotic LCCA occlusion, (2) inhibited ex viuo platelet aggregation, (3) minimized platelet deposition on injured vascular endothelium and within formed thrombi. and (4) stabilized CBF during 5 h ofcontinuous direct currrent induced intimal injury of the LCCA. introduction
The interaction of blood platelets with the endothelial surface of injured blood vessels as well as with other platelets is associated with the development of serious thromboembolic disorders and is a major factor in coronary artery thrombosis and reocclusion after successful angioplasty and or thrombolytic therapy (DeWood et al., 1980; Harrison et al., 1984 : Gold et al., 1986 Bates et al., 1987; Golino et al., 1988) . Recent knowledge regarding platelet surface receptors suggest that they participate in both platelet--endothelial cell adhesion and platelet-platelet interaction leading to aggregation (Sakariassen et al., 1986) . Platelet adhesion, consisting of a single layer of cells, at the site of vessel injury is essential for hemostasis and offers a minimal threat to the formation of an occlusive thrombus.
Conversely, intravascular platelet aggregation involves the formation of a platelet-fibrin mass which has the potential to embolize or to form an obstructive lesion. The agonists that are thought to initiate platelet aggregation in z&o (adenosine, ADP, epinephrine, collagen and thrombin) are dependent upon the binding of fibrinogen or other ligands to the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor (Coller et al., 1983; Coller, 1985 ; Coller and Scudder, 1985 and Scudder, 1985) .
In the present study we explored the antithrombotic efficacy of a murine monoclonal antibody [7E3 F(ab') and the data were expressed as a percent of the total left ventricular weight.
Platelet studies
Platelet counts and ex viva aggregation studies were performed at baseline, 1 h and 5 h after treatment was given. The platelet count was determined with a Haema Count MK-4/HC platelet counting system. Platelet rich plasma (PRP) was prepared from venous blood, using 3.2% sodium citrate as the anticoagulant and the supernate was harvested after centrifugation at 1000 r/min for 5 min ( 140 X g). Platelet poor plasma (PPP) was prepared by centrifuging the remaining blood at 12 000 x g for 10 min and discarding the cells. The platelet count of the PRP was determined and then diluted with PPP to achieve a cell count of 200000/mm3. Platelet aggregation was determined by established spectrophotometric methods using a four-channel aggregometer (BioData-PAP-4) and recording the increase in light transmission through a stirred suspension of PRP maintained at 37°C (Mills and Roberts, 1967 
Radiolabeling of platelets with Ill-indium oxine
Before the thoracotomy, blood (43.5 ml) was withdrawn from the internal jugular cannula into a plastic syringe containing 7.5 ml of 3.2% sodium citrate. The blood was centrifuged at 220 x g and the supernatant PRP was removed and the platelets were washed with acidified (pH 6.5) calcium-free Tyrode's buffer containing 0.3 mM EDTA and 0.35% bovine serum albumin as described previously (Thakur et al., 1976) . The washed platelets were resuspended gently in 10 ml of Tyrode's buffer and incubated for 15 min at room temperature with 500 &i '"iridium oxine (Diagnostic Isotopes, Inc., NJ). The PRP was centrifuged at 1000 x g for 10 min to remove radioactivity not bound to the platelets. The labeled platelets were resuspended in 5 ml of buffer and injected via the left atria1 cannula. Samples were taken during the procedure so that labeling efficiency could be determined (Romson et al., 1982) . Fifteen minutes after injecting the "'indium oxine labeled platelets, samples of blood were taken from the internal jugular cannula to determine recovery of the radiolabel. Blood was collected 1 h and 5 h after treatment with either the platelet antibody or normal saline for determining recovery of the radiolabel (Porter-Fink and Eckhauser, 1981) . If the artery had occluded, the sample was not obtained.
In the studies conducted with "'iridium oxine labeled platelets, the distribution of the radiolabel was determined in the thrombus, LCCA and left anterior descending coronary artery (LAD).
A 2 to 3 cm segment of the LAD was dissected free and cut into three segments (proximal, middle and distal) which served as the reference for radiolabeled counts (Fig. I) The specimens were fixed for 24 h at 4°C in a solution of 1 .O% glutaraldehyde (v/v) in 0.1 M cacodylate buffer (pH 7.4). The samples then were dehydrated in a graded series of ethanol solutions, washed in hexamethyl dysilazane and desiccated by critical point drying.
The samples were sputter coated with 15 nm of gold spliced paladium (AuPd) and were examined with an AMR 1200 scanning electron microscope.
Statistical analyses
The data are expressed as the mean rf: S.E.M. Differences between groups were determined by Student's t-test, when applicable, and were considered significant if P < 0. vs. antibody 16.5 + 0.6 kg. There was no significant difference in either the weight of the hearts determined at post mortem (control 149 f 10 g vs. antibody 139 + 10 g) or the percentage of the total left ventricle subserved by the left circumflex coronary artery (control 30.4 * 3.0% vs. antibody 31.4 f 4.5% j. The two groups did not differ with respect to their hemodynamic parameters which were recorded at the beginning of the experimental protocol (heart rate, blood pressure, coronary blood flow).
Left circumjex coronary artery bloodjow and coronary artery thrombosis At the initiation of each experiment, left circumflex coronary blood flow (CBF) did not differ significantly between the two groups: control 23.5 + 1.5 ml/min vs. antibody 27.3 + 3.0 ml/min.
Over the course of the experimental protocol, CBF was unchanged in the 7E3 antibody treated group and was at a mean value 21.5 + 3.1 ml/min when recorded 5 h after initiation of the electrolytic lesion in the circumflex coronary artery (Table  I ). In the control group CBF decreased progressively over time, as a reflection of the intravascular thrombus which formed in each case. By the 5 h time point, each of the animals in the control group had developed an occlusive intracoronary thrombus and CBF was negligible. The difference in CBF between the two Expressed as mean k standard error. ' P < 0.001, compared to control at same time point. nvaluesforcontrol:baseline= 13: 1 h = 13:2h = 13;3h = 5;4h = 1. n values for 7E3 : 6 at all times.
groups nearly achieved statistical significance at the end of the first hour of anodal current stimulation : control 17.5 + 2.4 ml/min vs. antibody 24.7 + 3.5 ml/min, P = 0.054. The difference in CBF between the two groups was significantly different at subsequent hourly recording: 2 h and 3 h. By 4 h and 5 h, the number of animals in the control was too few to allow for statistical analysis (P < 0.001 in each case). As the CBF diminished in the control group, there were spontaneous reactive hyperemic responses or oscillations where flow decreased to zero, then abruptly and spontaneously resumed at a rate higher than the preceding flow. The oscillations in the coronary flow did not occur in the antibody treated group (control 2.2 f 0.7 oscillations vs. antibody 0 + 0 oscillations, P < 0.05).
The time to thrombosis in the control group was 136 f 15 min (n = 13) compared to the antibody group (n = 6) in which none of the vessels became occluded during the 300 min (5 h) observation period (P < 0.001). At the conclusion of each experiment, the left circumflex coronary artery was opened longitudinally and, when present, the thrombus was recovered intact and weighed.
The thrombus weight determined after 30 min of thrombotic occlusion in the control group was 8.8 f 1.3 mg which was significantly larger than in the 7E3 F(ab')z antibody group, 2.2 + 1.1 mg (P < 0.001). In the control group thrombotic coronary artery occlusion developed in each animal, while in the antibody treated group small non-occlusive thrombi were found in three arteries, but all arteries were patent after 5 h of anodal current stimulation.
It is noteworthy that the non-occlusive thrombi did not appear to disrupt or to diminish CBF. Thus, factors other than the presence of a small intravascular thrombi may interfere with coronary artery blood flow.
Hemodynamic responses
In both the control and 7E3 F(ab'), antibody treated groups, the main hemodynamic parameters (heart rate and blood pressure) remained essentially unchanged throughout the experimental period (Table 1 ). The heart rate and mean arterial blood pressure did not differ between the two groups when the number of control animals was large enough to allow for analysis. After the second hour of observation, there were progressively fewer animals remaining in the control group: 3 h (n = 2), 4 h (n = 2), and 5 h (n = 1). The rapid attrition within the control group was due to the fact that experiments were terminated 30 min after blood flow in the circumflex coronary artery had ceased as a result of an occlusive thrombus having formed in response to intimal injury.
Platelet studies
The circulating platelet counts did not change over time and did not differ significantly between the two groups at any time point in the experimental protocol, when the number of control animals was large enough to allow for comparison.
The platelet counts in the control and treated group before administration of the antibody were: 453 + 47 x 103/ mm3 (n = 13) and 313 + 25 x 103/mm3 (n = 6). One hour after administration of The cx uivo responsiveness of platelets to 2.5 PM ADP in those dogs that were subsequently randomized to antibody treatment was lower at baseline than the control platelets ( §P < 0.05). However, the responsiveness of these same platelets to the higher concentration of ADP (5.0 PM) was similar to that of the platelets from control animals at baseline. Treatment with the monoclonal platelet antibody 7E3 F(ab')z significantly decreased platelet aggregation compare to baseline and the control group at 1 h (*P < 0.05). After 5 h, platelet antibody 7E3 F(ab'), significantly decreased platelet aggregation compared to baseline (*P < 0.05), however only one dog remained in the control group so this comparison could not be made. Data are mean + S.E.M. (b) Platelet aggregation induced with arachidonic acid. When two concentrations of aracbidonic acid (0.325 rnM and 0.65 mM) were used with epinephrine primed platelets (550 nM), aggregation was similar at baseline in the two treatment groups. Monoclonal platelet antibody 7E3 F(ab')* significantly decreased platelet aggregation compared to baseline and to the control group at 1 h ('P < 0.001). After 5 h, platelet antibody 7E3 F(ab'), significantly decreased platelet aggregation compared to baseline (*P < O.OOl), however, only one dog remained in the control group so this comparison could not be made. Data arc mean +-s.E.M. diluent or the 7E3 F(ab')t antibody, the res 9 ective platelet counts were 397 If: 63 x 10 /mm3 (n = 13) and 300 + 42 x 103/mm3 (n = 6) (P = N.S.). After 5 h, the platelet count in the 7E3 F(ab'), antibody treated group was 37 1 + 63 x 103/mm3 (n = 6).
One hour after vehicle administration in the control group there was no change from the baseline aggregation values [ Fig. 2(a) ]. After antibody treatment there was a significant decrease in platelet aggregation compared to baseline or to the control group at 1 h, P < 0.05 for ADP, P < 0.001 for AA [ Fig.  2(b) artery was observed in the group which was treated with 7E3 F(ab')z antibody. When the left anterior descending and circumflex coronary arteries from each dog were sectioned into proximal, middle, distal segments, the ratios of radioactivity between the LCCA/LAD segments were much lower in the antibody treatment group when compared to the control group (Fig. 3) . Platelets were able to adhere to the surface of the vessel wall to a limited extent in the 7E3 F(ab'), antibody treated group as evidenced from the presence of the radioactive counts. There was a significant inhibition of further accumulation of platelets by superimposition upon the adherent surface of thrombocytes, thereby impeding the full development of an occlusive thrombus.
The l1 'indium labeled platelets Anodal current injury of the left circumflex coronary artery was induced in animals which served as vehicle controls (m) and in animals which received the 7E3 F(ab'), antibody (0). Segments of the left anterior descending coronary artery (LAD) served as a reference. Three segments of each artery were weighed and gamma emission determined as ct/min/g of tissue. A ratio was calculated for purposes of comparison (LCCA/LAD). In the control dogs (n = 3), the ratios were higher than in the 7E3 F(ab'), treated dogs (n = 6, *f'< 0.05 for each segment of artery).
Of the three contiguous arterial segments, the segment distal to the placement of the anodal stimulation electrode had the greatest incorporation of "'iridium labeled platelets which coincided with the presence and distribution of the thrombus within the vessel.
control group (2 100 + 1200 ct/min/g, n = 3 ; P < 0.05).
Analysis of plasma antibody concentrations
Plasma from four dogs was analyzed before and at 1 h and 5 h after administration of 7E3 Flab'),
antibody. Flow cytometric analysis showed the linear mean intensity of test cells (5000 platelets) incubated with platelet poor plasma at baseline was 0.64 + 0.08 and increased to 1.03+0.11 at 1 h and 12.03 + 0.33 at 5 h. There was a significant amount of excess antibody in the plasma over the time course of the experimental protocol with the administered dose of the 7E3 F(ab'), antibody.
The slight increase at 5 h suggests the antibody may not be irreversibly bound to the platelets. The presence of antibody excess in the plasma assured that the antibody concentration would not be limiting and that all available platelet glycoprotein GPIIb/IIIa receptors could be inhibited effectively by binding to the F(ab') 2 . material which is adherent at the site of vessel injury (Fig. 4) . The ability of the 7E3 F(ab'), antibody to prevent platelet aggregation and subsequent thrombus development on the damaged endothelium is illustrated in Figure 5 which shows relatively few clusters of platelets adherent in the area of the disrupted endothelium with minimal fibrinous material present in the denuded area. Despite the thrombogenic potential of the injured intimal surface, occlusive thrombus formation did not occur in the presence of the 7E3 F(ab')z antibody.
Discussion
The experimental model of coronary artery thrombosis
The canine model employed in this study possesses anatomic features of coronary artery thrombosis in which an occlusive vascular lesion develops in response to vessel wall intimal injury in a region of high-grade stenosis. The application of an anodal current to the intimal surface of the coronary artery has been shown to be a reliable means of producing a thrombogenic substrate upon which platelets and blood clotting factors will interact and result in the formation of a thrombus mass (Romson et al. 1980a (Romson et al. , b, 1982 et al., 1983; Coller, 1985; Caller and Scudder, 1985 ; Sakariassen et al., 1986) (Coller and &udder, 1985 ; Coller et al., 1985) . The antibody has been demonstrated to have a high specificity for platelets and megakaryocytes, thus restricting its effect to these cells (Coller et al., 1983) and to cross react with the GPIIb/IIIa receptor on platelets of primates and dogs (Coller et al., 1986 The 7E3 monoclonal platelet antibody did not exhibit significant hemodynamic effects as suggested by the failure to alter heart rate and blood pressure. In both groups the platelet count was not affected by the experimental protocol.
The use of the murine monoclonal 7E3 F(ab') z fragments did not result in a reduction in the circulating platelet count. A similar benign response to the F(ab'), fragments has been confirmed in several other models using various animal species (Coller et al., 1986; Gold et al., 1988; Hanson et al., 1988) . Coincident with the presence of the 7E3 F(ab'), on the GPIIb/IIIa receptor is the observation that the ex V&JO inhibition of ADP or arachidonic acid induced platelet aggregation persisted for 5 h after the antibody had been administered.
Others have observed even longer inhibition of platelet aggregation, up to 48 h, with minimal bleeding complications.
( Hanson et al., 1988) . The "'iridium labeled platelets which subsequently were exposed to antibody did not adhere to the coronary vascular endothelium to the same degree as was observed to occur in the control group of animals. Several methods of vascular injury, including electrically induced deep venous thrombosis and endothelial denudation of the femoral and carotid artery of the dog, are known to cause accumulation of platelets detectable by il'indium labeling (Thakur et al., 1976) . The radioactivity ratios in the coronary arterial segments were less in the vessel specimens obtained from antibody treated dogs, thereby suggesting that fewer platelets had adhered to the vessel wall at the site of intimal injury. The resulting thrombus was decreased significantly in overall mass. The ultimate thrombus mass was smaller in the presence of 7E3 F(ab'), and the concentration of the radiolabe1 was less in the thrombi recovered from the vessels of animals which received antibody. Because fewer platelets are present, the accumulated mass necessary to obstruct the vessel or the amount of mediators released to evoke the other components of the thrombus (fibrin and neutrophils)
are not present. A decrease in the number of platelets incorporated into the thrombus mass might also be associated with a decrease in the local production of fibrinolytic inhibitors which would delay the process of fibrinolysis (24). The development of smaller thrombi may result from retarding or inhibiting those events which lead to platelet accretion on the surface of the thrombus while at the same time permitting unopposed expression of endogenous fibrinolytic mechanisms. It is uncertain whether the local decrease in the number of accumulated platelets and/or the inhibition of aggregation and mediator release account for the observed stabilization of the coronary blood flow in the presence of a nonocclusive thrombus.
Conclusions
The intravenous administration of the murine monoclonal 7E3 F(ab')z platelet antibody did not produce any adverse effects upon the recorded cardiovascular parameters as evidenced by a failure to alter heart rate, blood pressure, or coronary artery blood flow. In addition the circulating platelet count was unaltered and bleeding or excessive blood loss was not a complication.
Whereas the antibody did not achieve a complete prevention of thrombus formation, it did result in a significant decrease in the ultimate size of the thrombus mass thereby preserving coronary artery blood flow.
The 7E3 F(ab'), platelet antibody may alter the rate of incorporation of functionally intact platelets into the thrombus mass which forms in response to intimal injury in the coronary artery. The latter would result in a
